RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE

Hepion Pharmaceuticals P/S 2024

Hepion Pharmaceuticals P/S

0

Hepion Pharmaceuticals Dividend yield

Ticker

HEPA

ISIN

US4268971045

WKN

A2PN6W

As of Apr 28, 2024, Hepion Pharmaceuticals's P/S ratio stood at 0, a 0% change from the 0 P/S ratio recorded in the previous year.

The Hepion Pharmaceuticals P/S history

Hepion Pharmaceuticals Aktienanalyse

What does Hepion Pharmaceuticals do?

Hepion Pharmaceuticals Inc. is a biopharmaceutical company focused on researching and developing therapeutics for the treatment of liver diseases. The company was founded in 2013 and is headquartered in Edison, New Jersey. The history of Hepion Pharmaceuticals Inc. began with the discovery of a new approach to treating liver diseases. Researchers found that small molecules targeting specific cells in the liver could have a positive effect on liver function. Hepion used this discovery as a starting point for developing new drugs to treat liver diseases. Hepion Pharmaceuticals Inc.'s business model is based on the development and marketing of innovative therapeutics for a variety of liver diseases, including fatty liver disease, alcoholic liver disease, non-alcoholic steatohepatitis (NASH), liver fibrosis, liver cirrhosis, and liver cancer. Hepion Pharmaceuticals has several divisions, all focused on the development of therapeutics for liver diseases. The primary division is research and development, which focuses on identifying and developing new drugs for the liver. Another important division is clinical development, where the drugs are tested and validated in clinical trials. The third division is marketing, where the therapeutics are marketed and sold. Hepion Pharmaceuticals Inc. currently offers two products. The first product is CRV431, a top-notch inhibitor of cytokine-mediated signaling. It is an orally administered drug specifically developed for the treatment of liver fibrosis. CRV431 aims to inhibit cytokine-mediated signaling responsible for fibrosis formation. The second product is an idiosyncratic database marketed under the name AI-Enabler. It is touted by the company as a groundbreaking tool for more precise medicine and research in support of drug development work. Overall, Hepion Pharmaceuticals Inc. is a promising biopharma company with a clear focus on developing new drugs for the treatment of liver diseases. With its innovative products and expertise in research and development, the company collaborates closely with partners from the scientific, industrial, and governmental sectors. It is hoped that this company will make further pioneering discoveries in the future and contribute to the benefit of human health. Hepion Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

P/S Details

Decoding Hepion Pharmaceuticals's P/S Ratio

Hepion Pharmaceuticals's Price to Sales (P/S) Ratio is a crucial financial metric that measures the company's market valuation relative to its total sales revenue. It's calculated by dividing the company's market capitalization by its total sales over a specific period. A lower P/S ratio can indicate that the company is undervalued, while a higher ratio may suggest overvaluation.

Year-to-Year Comparison

Comparing Hepion Pharmaceuticals's P/S ratio yearly provides insights into how the market perceives the company’s value relative to its sales. An increasing ratio over time can indicate growing investor confidence, while a decreasing trend might reflect concerns about the company’s revenue generation capabilities or market conditions.

Impact on Investments

The P/S ratio is instrumental for investors evaluating Hepion Pharmaceuticals's stock. It offers insights into the company’s efficiency in generating sales and its market valuation. Investors use this ratio to compare similar companies within the same industry, aiding in selecting stocks that offer the best value for investment.

Interpreting P/S Ratio Fluctuations

Variations in Hepion Pharmaceuticals’s P/S ratio can result from changes in the stock price, sales revenue, or both. Understanding these fluctuations is crucial for investors to evaluate the company’s current valuation and future growth potential, aligning their investment strategies accordingly.

Frequently Asked Questions about Hepion Pharmaceuticals Stock

What is the price-to-earnings ratio of Hepion Pharmaceuticals?

The price-earnings ratio of Hepion Pharmaceuticals is currently 0.

How has the price-earnings ratio of Hepion Pharmaceuticals changed compared to last year?

The price-to-earnings ratio of Hepion Pharmaceuticals has increased by 0% fallen (meaning "decreased" or "dropped") compared to last year.

What consequences does a high price-earnings ratio have for investors?

A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.

What does a low price-earnings ratio mean?

A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.

Is the price-earnings ratio of Hepion Pharmaceuticals high compared to other companies?

Yes, the price-to-earnings ratio of Hepion Pharmaceuticals is high compared to other companies.

How does an increase in the price-earnings ratio of Hepion Pharmaceuticals affect the company?

An increase in the price-earnings ratio of Hepion Pharmaceuticals would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.

How does a reduction in the price-to-earnings ratio of Hepion Pharmaceuticals affect the company?

A decrease in the price-earnings ratio of Hepion Pharmaceuticals would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.

What are some factors that influence the price-earnings ratio of Hepion Pharmaceuticals?

Some factors that influence the price-earnings ratio of Hepion Pharmaceuticals are the company's growth, financial position, industry development, and the overall economic situation.

How much dividend does Hepion Pharmaceuticals pay?

Over the past 12 months, Hepion Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Hepion Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of Hepion Pharmaceuticals?

The current dividend yield of Hepion Pharmaceuticals is .

When does Hepion Pharmaceuticals pay dividends?

Hepion Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Hepion Pharmaceuticals?

Hepion Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Hepion Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Hepion Pharmaceuticals located?

Hepion Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Hepion Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Hepion Pharmaceuticals from 4/28/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 4/28/2024.

When did Hepion Pharmaceuticals pay the last dividend?

The last dividend was paid out on 4/28/2024.

What was the dividend of Hepion Pharmaceuticals in the year 2023?

In the year 2023, Hepion Pharmaceuticals distributed 0 USD as dividends.

In which currency does Hepion Pharmaceuticals pay out the dividend?

The dividends of Hepion Pharmaceuticals are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Hepion Pharmaceuticals stock can be added to a savings plan with the following providers: Trade Republic

Andere Kennzahlen von Hepion Pharmaceuticals

Our stock analysis for Hepion Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Hepion Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.